Abstract
Patients with previously untreated squamous cell lung carcinomas were evaluated to see if combining the expression of molecular and cellular factors with the most important clinical prognostic factors could improve the diagnostic ability to predict prognosis. For this reason, immunohistochemistry was used to examine the squamous cell lung carcinomas from 121 patients for their expression of ERBB-1, vascular endothelial growth factor (VEGF), cyclin A, FOS, JUN and MYC. Median survival was shorter for patients with ERBB-1-, VEGF-, cyclin A-, FOS-, or JUN-positive tumours. For those patients with positive lymph node involvement, the survival times were also shorter in the VEGF-positive, cyclin A-positive and FOS-positive groups. Multivariate analysis independently demonstrated a significant prognostic value for lymph node involvement, VEGF and FOS.
Highlights
We evaluated whether or not combining the expression of the above-mentioned factors with the most important clinical prognostic factors can improve the prognostic value for patients with squamous cell lung carcinomas
The overall prognosis of patients with squamous cell lung carcinomas is mainly determined by tumour extent (T) and lymph node involvement (LN)
We investigated separately vascular endothelial growth factor (VEGF), ERBB 1, FOS and cyclin A for their prognostic value when combined with lymph node involvement (LN)
Summary
Patients with previously untreated squamous cell lung carcinomas (n = 121) were admitted into this study. They had received surgical treatment in the Chest Hospital Heidelberg-Rohrbach (Director, Professor Dr I Vogt-Moykopf) between 1980 and 1983. The morphological classification of the carcinomas was conducted according to the WHO study (1981). According to the guidelines of the American Joint Committee on Cancer (Carr and Mountain, 1977), all patients were staged at the time of their surgery. The USCC classification from 1987 was not used because the patients had been operated on previously. A restaging according to the new guidelines was not possible, because not all the criteria for tumour staging were definitive.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
